KK2269
/ Kyowa Kirin
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
March 06, 2024
KK2269, an epithelial cell adhesion molecule-targeted CD40 agonist, stimulates anti-tumor immunity resulting in sustained anti-tumor effect against mouse intrahepatic tumor without hepatotoxicity
(AACR 2024)
- "In addition, KK2269 in combination with docetaxel showed potent antitumor effect accompanied by T-cell infiltration and activation against the intrahepatic tumor, which has a lower immune infiltration. These results suggest that the combination therapy of KK2269 and docetaxel is promising for metastatic EpCAM-positive tumors."
IO biomarker • Preclinical • Colon Cancer • Colorectal Cancer • Gastrointestinal Cancer • Hepatocellular Cancer • Liver Cancer • Lung Cancer • Oncology • Solid Tumor • CD40 • IL12B
March 06, 2024
KK2269, an epithelial cell adhesion molecule-targeted CD40 agonist, demonstrates antitumor effects in combination with standard therapies for NSCLC
(AACR 2024)
- "Docetaxel is used as a combination therapy with ramucirumab, an anti-VEGF receptor 2 (VEGFR2) antibody, for previously treated advanced NSCLC. Thus, a significant antitumor effect was demonstrated when KK2269 was added to the standard treatment of NSCLC (docetaxel + anti-VEGFR2 antibody) and to docetaxel + anti-PD-1 antibody. Our findings strongly suggest that KK2269 provides improved treatment options for patients with NSCLC."
Combination therapy • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • CD40
February 19, 2024
A Study of KK2269 in Adult Participants With Solid Tumors
(clinicaltrials.gov)
- P1 | N=71 | Recruiting | Sponsor: Kyowa Kirin, Inc.
Combination therapy • Monotherapy • New P1 trial • Esophageal Adenocarcinoma • Esophageal Cancer • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Gastrointestinal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor
1 to 3
Of
3
Go to page
1